Investigation of Aptinyx Inc.
Aptinyx Inc. (APTX)’s Drug Fails to Meet Primary Endpoint
On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial. On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98. The stock has yet to recover and currently trades at around $3.50, a 78% decline from its IPO price.
Aptinyx Inc. (APTX) Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information form below.